Veracyte CEO Marc Stapley Sells $6.9 Million in VCYT Stock
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
veracytevcyt
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A significant securities transaction for Veracyte occurred on 3 June 2026. CEO Marc Stapley sold $6.9 million worth of company shares, according to a filing submitted on 4 June 2026. The sale was executed at an average price of $27.63 per share. This transaction reduced Stapley's direct holdings by approximately 250,000 shares.
CEO stock sales often draw scrutiny for signaling executive sentiment about near-term valuation. The transaction precedes the company's Q2 2026 earnings report, scheduled for late July. It also follows a period of notable appreciation for Veracyte's stock, which gained 22% year-to-date through June 3.
The broader genomic diagnostics sector faces a complex macro backdrop. The iShares Genomics Immunology and Healthcare ETF (IDNA) is up 12% year-to-date, underperforming the S&P 500 Healthcare sector's 15% rise. Interest rate policy from the Federal Reserve remains a headwind for high-growth, cash-burn biotech firms. Veracyte has achieved operational profitability, which distinguishes it from many peers.
The immediate catalyst appears to be the stock's recent performance. A 22% gain in five months may have triggered pre-planned selling under a Rule 10b5-1 trading plan. Such plans allow executives to schedule sales in advance to avoid allegations of insider trading. The timing relative to the upcoming Q2 earnings blackout period is a standard consideration for such transactions.
The sale involved 249,800 shares of Veracyte common stock. The total value of $6.9 million represents one of the largest single CEO sell transactions for the company in recent years. Stapley’s direct ownership stake in Veracyte decreased from approximately 1.05 million shares to about 800,000 shares following the sale. This constitutes a 24% reduction in his directly held position.
The transaction price of $27.63 per share compares to key market levels. Veracyte’s 52-week high is $29.44, while its 52-week low is $19.85. The stock’s 50-day moving average stands at $25.90. The sale price represents a 6.7% premium to this medium-term trend indicator.
| Metric | Value | Comparison to Peer (Exact Sciences, EXAS) |
|---|---|---|
| YTD Performance | +22% | EXAS: +15% YTD |
| Market Capitalization | ~$2.1 Billion | EXAS: ~$11.2 Billion |
| Price/Sales Ratio (TTM) | 5.8x | EXAS: 4.2x |
Post-sale, Veracyte’s insider ownership float, including all officers and directors, remains above 5%. The company’s short interest ratio is 4.2 days to cover, slightly below the sector average of 4.8 days. Trading volume on the day of the filing was 1.2 million shares, 40% above the 30-day average.
The sale creates a neutral-to-cautious signal for Veracyte’s stock in the near term. Large, concentrated selling by a CEO can temporarily weigh on share price momentum. The transaction may prompt profit-taking from momentum traders who rode the 22% YTD gain. This flow could shift toward larger, more liquid genomic peers like Exact Sciences (EXAS) or Illumina (ILMN) in the short run.
A key counter-argument is the prevalence of 10b5-1 planned sales. If this sale was scheduled months in advance, it may reflect no new negative insight into the business. It simply represents prudent personal financial planning and diversification by the CEO. The maintained stake of 800,000 shares still represents a significant multi-million dollar commitment to Veracyte’s future.
Positioning data shows institutional ownership of VCYT remains stable at 92% of the float. The sale is unlikely to trigger major portfolio rebalancing from large funds. However, retail and quantitative investors may interpret the filing as a technical headwind. Flow is likely to remain muted until the next earnings report provides a fundamental catalyst.
Investor focus now turns to Veracyte’s Q2 2026 earnings report, expected in late July. Key metrics will include revenue growth for its Afirma and Percepta genomic tests and updates on its minimal residual disease pipeline. The conference call may address questions about the CEO’s transaction and the company’s capital allocation strategy.
A critical level to watch is the $25.50 support zone, which aligns with the 100-day moving average. A sustained break below this level could signal a deeper technical correction. Resistance sits near the recent $28.50 high. Volume trends over the next two weeks will indicate whether selling pressure is continuing or abating.
Beyond earnings, sector-wide sentiment will be influenced by the J.P. Morgan Healthcare Conference in January 2027. Regulatory updates from the Centers for Medicare & Medicaid Services on reimbursement rates for genomic tests, typically released in the fourth quarter, are another major catalyst. Performance of the broader IDNA ETF will also impact Veracyte’s relative valuation.
Not necessarily. Executives sell shares for many reasons unrelated to company performance, such as tax planning, diversification, or funding major personal expenses. Many sales are executed under pre-arranged 10b5-1 plans set up months in advance. The key context is the size of the sale relative to the executive's total holdings and the pattern of historical transactions.
A Rule 10b5-1 plan is a formal arrangement that allows company insiders to buy or sell a predetermined number of shares at a predetermined time. It is established when the insider does not possess material non-public information. The plan then executes automatically, providing a defense against allegations of insider trading. Marc Stapley's recent sale was likely executed under such a plan.
Veracyte trades at a premium to some peers based on price-to-sales. Its 5.8x TTM P/S ratio is higher than Exact Sciences' 4.2x but lower than more speculative early-stage genomic companies. This premium reflects Veracyte's profitability and its focus on proprietary tests in thyroid, lung, and prostate cancer, which have established commercial traction and reimbursement pathways.
The CEO's $6.9 million sale is a significant liquidity event that introduces near-term technical pressure, but the maintained $22 million stake confirms continued long-term alignment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.